182 related articles for article (PubMed ID: 19639319)
1. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production.
Hashizume M; Uchiyama Y; Horai N; Tomosugi N; Mihara M
Rheumatol Int; 2010 May; 30(7):917-23. PubMed ID: 19639319
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.
Song SN; Tomosugi N; Kawabata H; Ishikawa T; Nishikawa T; Yoshizaki K
Blood; 2010 Nov; 116(18):3627-34. PubMed ID: 20644113
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis.
Uchiyama Y; Yorozu K; Hashizume M; Moriya Y; Mihara M
Biol Pharm Bull; 2008 Jun; 31(6):1159-63. PubMed ID: 18520048
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients.
Song SN; Iwahashi M; Tomosugi N; Uno K; Yamana J; Yamana S; Isobe T; Ito H; Kawabata H; Yoshizaki K
Arthritis Res Ther; 2013 Oct; 15(5):R141. PubMed ID: 24286116
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
Kawabata H; Tomosugi N; Kanda J; Tanaka Y; Yoshizaki K; Uchiyama T
Haematologica; 2007 Jun; 92(6):857-8. PubMed ID: 17550864
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production.
Uchiyama Y; Yoshida H; Koike N; Hayakawa N; Sugita A; Nishimura T; Mihara M
Int Immunopharmacol; 2008 Nov; 8(11):1595-601. PubMed ID: 18664393
[TBL] [Abstract][Full Text] [Related]
7. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys.
Mihara M; Kotoh M; Nishimoto N; Oda Y; Kumagai E; Takagi N; Tsunemi K; Ohsugi Y; Kishimoto T; Yoshizaki K; Takeda Y
Clin Immunol; 2001 Mar; 98(3):319-26. PubMed ID: 11237555
[TBL] [Abstract][Full Text] [Related]
8. Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model.
Kato A; Matsuo S; Takai H; Uchiyama Y; Mihara M; Suzuki M
Exp Mol Pathol; 2008 Jun; 84(3):262-70. PubMed ID: 18511040
[TBL] [Abstract][Full Text] [Related]
9. Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells.
Noguchi-Sasaki M; Sasaki Y; Shimonaka Y; Mori K; Fujimoto-Ouchi K
BMC Cancer; 2016 Apr; 16():270. PubMed ID: 27068103
[TBL] [Abstract][Full Text] [Related]
10. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis.
Takagi N; Mihara M; Moriya Y; Nishimoto N; Yoshizaki K; Kishimoto T; Takeda Y; Ohsugi Y
Arthritis Rheum; 1998 Dec; 41(12):2117-21. PubMed ID: 9870868
[TBL] [Abstract][Full Text] [Related]
11. A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential.
Liu X; Li L; Wang Q; Jiang F; Zhang P; Guo F; Liu H; Huang J
Front Immunol; 2021; 12():816646. PubMed ID: 35126375
[TBL] [Abstract][Full Text] [Related]
12. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
13. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys.
Schwoebel F; van Eijk LT; Zboralski D; Sell S; Buchner K; Maasch C; Purschke WG; Humphrey M; Zöllner S; Eulberg D; Morich F; Pickkers P; Klussmann S
Blood; 2013 Mar; 121(12):2311-5. PubMed ID: 23349391
[TBL] [Abstract][Full Text] [Related]
14. Rheumatoid anemia.
Masson C
Joint Bone Spine; 2011 Mar; 78(2):131-7. PubMed ID: 20851655
[TBL] [Abstract][Full Text] [Related]
15. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
Van Roy M; Ververken C; Beirnaert E; Hoefman S; Kolkman J; Vierboom M; Breedveld E; 't Hart B; Poelmans S; Bontinck L; Hemeryck A; Jacobs S; Baumeister J; Ulrichts H
Arthritis Res Ther; 2015 May; 17(1):135. PubMed ID: 25994180
[TBL] [Abstract][Full Text] [Related]
16. Anemia in monkey collagen-induced arthritis is correlated with serum IL-6, but not TNFalpha.
Uchiyama Y; Koike N; Mihara M
Rheumatol Int; 2008 Jul; 28(9):879-83. PubMed ID: 18309490
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
[TBL] [Abstract][Full Text] [Related]
18. [The clinical significance of hepcidin detection in the patients with anemia and rheumatoid arthritis].
Galushko EA
Klin Med (Mosk); 2014; 92(6):21-7. PubMed ID: 25799826
[TBL] [Abstract][Full Text] [Related]
19. Anti-TNF-
Shu W; Pang Z; Xu C; Lin J; Li G; Wu W; Sun S; Li J; Li X; Liu Z
Mediators Inflamm; 2019; 2019():4038619. PubMed ID: 31814801
[TBL] [Abstract][Full Text] [Related]
20. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis.
Isaacs JD; Harari O; Kobold U; Lee JS; Bernasconi C
Arthritis Res Ther; 2013; 15(6):R204. PubMed ID: 24295403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
